Safety and efficacy of thymoglobulin (ATG) for cord blood transplantation for hematologic malignancies

Not Applicable

• Conditions: Hematologic malignancies with an indication for allogeneic hematopoietic stem cell transplantation (allo- HSCT) Acute myeloid leukemia Myelodysplastic syndrome Chronic myeloid leukemia Malignant lymphoma Acute lymphoblastic leukemia

• Registration Number: JPRN-UMIN000004206
• Lead Sponsor: Hematology, Osaka City University, Graduate School of Meicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-09-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

Not provided

Exclusion Criteria

(1)Major organ dysfunction: (a)Ejection fraction: <30% (b)Pulmonary function test: %VC<30%, FEV1.0% <40%, or SaO2 <90% on room air (c)Serum creatinine: >2.0mg/dl (d)Liver function: total bilirubin >2.0mg/dl, AST or ALT >3 x UNL, or patients with chronic active hepatitis or liver cirrhosis (2)Poorly controlled hypertension (3)HIV antibody positivity (4)Uncontrolled active infection (5)Uncontrolled CNS invasion (6)Pregnant, nursing or possibly pregnant woman (7)Patients with severe mental disorder who are likely unable to participate in the study (8)Known hypersensitivity or allergy to any of the drugs in the conditioning regimen of this transplant, or drugs used for GVHD prophylaxis (9)Patients with positive donor-specific HLA antibodies(DSA) (10)Patients with graft failure following allegeneic hematopoietic stem cell transplantation (11)No indication for this study as judged by physician in charge. Note: HBs antigen positivity and HCV antibody positivity is not excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified